Research is focused on identifying novel agents for the treatment of relapsed sarcomas (specifically rhabdomyosarcoma, osteosarcoma, and Ewings sarcoma) based on results of precision genomics testing utilizing deep sequencing, transcriptome, proteome, and IHC data in patients. In parallel with the clinical component of this project, laboratory based evaluation of patient-derived cell lines, and preclinical xenograft models developed from this same population of patients will allow broader evaluation of potential therapeutic options as well as discovery of novel targets via a comprehensive ‘omic’ investigation.
Research: Pediatric Cancer Precision Genomics, Sarcomas.
